Intervention

SI-B003

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting3

Common conditions5

Lead sponsors shown1

Clinical trials

5 shown

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsNCT05956587 · 2024-01-29

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerNCT06042894 · 2023-12-12

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerNCT05924841 · 2023-11-10

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerNCT05949606 · 2023-10-30

ACTIVE_NOT_RECRUITING

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsNCT04606472 · 2020-11-10

ACTIVE_NOT_RECRUITING

Common conditions

Non-small Cell Lung Cancer2 Breast Cancer1 Nasopharyngeal Carcinoma1 Small Cell Lung Cancer1 Solid Tumor1

Leading sponsors

Sichuan Baili Pharmaceutical Co., Ltd.5

Trial status mix

RECRUITING3

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE24

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.